Varices in Early Histological Stage Primary Biliary Cirrhosis
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND/GOALS: Esophageal varices (EV) in early histological stages of primary biliary cirrhosis (PBC) have been recognized but not well defined. We sought to determine the prevalence, clinical characteristics, and predictors of EV in early-stage PBC, as well as to evaluate the effectiveness of recent guidelines regarding EV screening in PBC patients. STUDY: We retrospectively reviewed the charts of 325 PBC patients who had undergone complete evaluation before enrollment into 2 large clinical trials at the Mayo Clinic. RESULTS: Nineteen percent (62/325) of our patient population had EV on esophagogastroduodenoscopy; 6% (8/127) of early-stage PBC patients had EV. Ninety five percent of our PBC patients with varices met at least one of the following conditions: male sex, low albumin (<3.5 g/dL), elevated bilirubin level (≥1.2 mg/dL), and/or prolonged prothrombin time (≥12.9 s). The sensitivity and specificity of these variables in combination to predict the presence of varices were 95% and 55%, respectively. Serum bilirubin ≥1.2 mg/dL and albumin <3.5 were independent predictors of varices with hazard values of 5.4 and 3.5 respectively. CONCLUSIONS: EV can occur in a minority of early-stage PBC patients. Various models may be used to identify PBC patients who are candidates for screening esophagogastroduodenoscopy for EV. Based on adequate performance and its simplicity, we propose that male sex, low albumin, elevated bilirubin, and/or prolonged prothrombin time be used as a model to noninvasively predict EV. Further validation is required.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In one study, however, [245] whilst 6% (8/127) of early-stage patients with PBC had varices, 95% of patients with varices, nevertheless had markers of highrisk disease: male sex, low albumin, elevated bilirubin, and/or elevated INR.”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [245]
In the citing paper
“One study showed that 6% of patients with PBC without cirrhosis had varices.(91)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [91]
In the citing paper
“It is important to note that patients with PBC can develop varices even in the absence of established cirrhosis, although in clinical practice pre-sinusoidal varices are relatively unusual.234–236”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [235]
Citations
Cites
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis
Garcia-Tsao, G., Sanyal, A. J., Grace, N. D., & Carey, W. (2007) · Hepatology · doi:10.1002/hep.21907 · Cited by 1,722
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationPrognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755 · cited 2×
“Exclusion criteria (in both studies) included the following: (1) previous treatment with UDCA, colchicine, corticosteroids, azathioprine, cyclosporine, chlorambucil, methotrexate, or d-penicillamine in the past 3 months; (2) anticipated need for liver transplantation within 1 year; (3) pregnancy; (4) age less than 18…”
BackgroundStaging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487 · cited 2×
“Exclusion criteria (in both studies) included the following: (1) previous treatment with UDCA, colchicine, corticosteroids, azathioprine, cyclosporine, chlorambucil, methotrexate, or d-penicillamine in the past 3 months; (2) anticipated need for liver transplantation within 1 year; (3) pregnancy; (4) age less than 18…”
BackgroundSelf-citationPRIMARY BILIARY CIRRHOSIS. CHRONIC NON-SUPPURATIVE DESTRUCTIVE CHOLANGITIS.
Rubin, E., Schaffner, F., & Pópper, H. (1965) · PubMed Central · Cited by 374
Nakamura, M., Kondo, H., Mori, T., Komori, A., Matsuyama, M., Ito, M., Takii, Y., Koyabu, M., Yokoyama, T., Migita, K., et al. (2007) · Hepatology · doi:10.1002/hep.21472 · Cited by 365
Cited by
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
“In one study, however, [245] whilst 6% (8/127) of early-stage patients with PBC had varices, 95% of patients with varices, nevertheless had markers of highrisk disease: male sex, low albumin, elevated bilirubin, and/or elevated INR.”
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“(90) Nodular regenerative hyperplasia is a known complication of PBC and should be differentiated from cirrhosis; it may also contribute to portal hypertension in noncirrhotic patients.(91) With the high disease specificity of a positive AMA test, the role of liver biopsy in diagnosing PBC is questionable when ALP act…”
BackgroundSelf-citationCarey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Self-citationHirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Moctezuma-Velazquez, C., Saffioti, F., Tasayco-Huaman, S., Casu, S., Mason, A., Roccarina, D., Vargas, V., Nilsson, J.-E., Tsochatzis, E., Augustin, S., et al. (2019) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0265-7 · Cited by 78
Metadata
- Authors
- Ali, A. H., Sinakos, E., Silveira, M. G., Jorgensen, R. A., Angulo, P., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2011-08
- Volume
- 45
- Issue
- 7
- Pages
- e66-e71
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2139223881
- Cited by
- 50
- References
- 27
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 7 · 2017: 4 · 2016: 4 · 2015: 2 · 2014: 1 · 2013: 4 · 2012: 1
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- primary biliary cirrhosis, esophageal varices, variceal screening, upper gastrointestinal endoscopy, serum albumin, serum bilirubin, prothrombin time, risk factors, non-invasive prediction model
- MeSH terms
- Adult, Aged, Cholagogues and Choleretics, Double-Blind Method, Esophageal and Gastric Varices, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Sensitivity and Specificity, Ursodeoxycholic Acid, Prevalence, Endoscopy, Gastrointestinal, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.